| 7.83 0.13 (1.69%) | 07-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 10.55 | 1-year : | 13.33 |
| Resists | First : | 9.04 | Second : | 11.42 |
| Pivot price | 8.3  |
|||
| Supports | First : | 5.19 | Second : | 4.31 |
| MAs | MA(5) : | 7.52  |
MA(20) : | 7.83 |
| MA(100) : | 8.99 |
MA(250) : | 13.44 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 22.1 |
D(3) : | 25.3 |
| RSI | RSI(14): 48.2 |
|||
| 52-week | High : | 51.59 | Low : | 5.19 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ RBOT ] has closed above bottom band by 33.9%. Bollinger Bands are 25.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 8.51 - 8.55 | 8.55 - 8.58 |
| Low: | 7.62 - 7.65 | 7.65 - 7.68 |
| Close: | 7.78 - 7.83 | 7.83 - 7.89 |
Vicarious Surgical Inc. engages in developing and selling single-incision surgical robot that virtually transports surgeons inside the patient to perform minimally invasive surgery. It offers Vicarious System, a single-incision surgical robot for ventral hernia repair. The company was incorporated in 2014 and is headquartered in Waltham, Massachusetts.
Tue, 16 Jul 2024
Vicarious Surgical (NYSE:RBOT) Price Target Lowered to $10.00 at Morgan Stanley - Defense World
Tue, 21 May 2024
Vicarious Surgical CEO sells shares worth $9,506 - Investing.com
Fri, 03 May 2024
Insiders Who Sold Vicarious Surgical Missed Out On 15% Stock Increase - Simply Wall St
Wed, 01 May 2024
Vicarious Surgical Inc. (NYSE:RBOT) Q1 2024 Earnings Call Transcript - Yahoo Finance
Mon, 29 Apr 2024
Vicarious Surgical Reports First Quarter 2024 Financial Results - Yahoo Finance
Wed, 06 Mar 2024
Vicarious presses forward with soft tissue robot despite struggles - MedTech Dive
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 5 (M) |
| Shares Float | 2 (M) |
| Held by Insiders | 30.7 (%) |
| Held by Institutions | 40.1 (%) |
| Shares Short | 196 (K) |
| Shares Short P.Month | 161 (K) |
| EPS | -11.4 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 14.31 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -40.8 % |
| Return on Equity (ttm) | -71.3 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -13.73 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -58 (M) |
| Levered Free Cash Flow | -33 (M) |
| PE Ratio | -0.69 |
| PEG Ratio | 0 |
| Price to Book value | 0.54 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.71 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|